ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/054/SRR22483854/SRR22483854_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/079/SRR22484279/SRR22484279_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/051/SRR22483851/SRR22483851_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/081/SRR22484281/SRR22484281_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/079/SRR22484279/SRR22484279_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/080/SRR22484280/SRR22484280_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/053/SRR22483853/SRR22483853_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/052/SRR22483852/SRR22483852_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/053/SRR22483853/SRR22483853_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/082/SRR22484282/SRR22484282_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/052/SRR22483852/SRR22483852_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/051/SRR22483851/SRR22483851_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/082/SRR22484282/SRR22484282_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/054/SRR22483854/SRR22483854_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/081/SRR22484281/SRR22484281_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR224/080/SRR22484280/SRR22484280_1.fastq.gzprimaryOK200GenomicsNanjing First Hospitalhttps://www.ebi.ac.uk/ena/browser/view/PRJNA907307This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual SeriesENAprotein translation, Post Translational Amino Acid Modification, Colorectal Neoplasm, 5 FU Medac, Post-Translational Protein Modifications, Colorectal Cancer, Carac, Neoplasms, Fluorouracil Monosodium Salt, Tumor, Haemato FU, Protein Processing, autosomal dominant, 5 Fluorouracil Biosyn, Fluorouracil-GRY, Flurodex, Posttranslational, Colorectal, colorectal cancer, Fluorouracil Mononitrate, Post Translational Modification, 2, Post-Translational Modifications, Fluoro Uracile ICN, Post Translational, Fluorouracil Potassium Salt, Colorectal Tumors, Modification, Post-Translational Protein, 5-Fluorouracil-Biosyn, Post-Translational, Efudex, Colorectal Carcinomas, 5 HU Hexal, Colorectal Tumor, Posttranslational Protein Processing, Fluracedyl, Fluorouracile Dakota, large intestine cancer, Protein Modifications, Fluorouracile, cancer of the large intestine, Post-Translational Amino Acid Modification, Posttranslational Amino Acid Modification, 3H)-Pyrimidinedione, Posttranslational Protein, 5-fluoro-, colorectal (colon or rectal) cancer., 5-Fluoropyrimidine-2, Dakota, somatic mutation, 5-FU, 5 FU Lederle, Tumors, Cancer, Post-Translational Modification, Carcinoma, protein anabolism, Fluorouracil Monopotassium Salt, 5-Fluorouracil, protein biosynthetic process, fluorouracil, Ribofluor, Modifications, 5-Fluoracil, 5-FU Medac, Post-Translational Protein Modification, Onkofluor, 5 Fluorouracil, RGD1304822, Post Translational Modifications, 4-dione, Efudix, protein formation, Neoplasm, Neofluor, protein biosynthesis, 4(1H, CRC, Colorectal Cancers, Protein Modification, Fluoro-Uracile ICN, Carcinomas, large bowel cancer, 5FU, 5-FU Lederle, Fluorouracilo Ferrer Far, Post Translational Protein Processing, mKIAA1627, Processing, susceptibility to, Colorectal Carcinoma, Adrucil, Cancers, Fluoruracil, cancer of large bowel, Fluorouracil, Post Translational Protein Modification, Fluoroplex, colon cancer, Amino Acid Modification, 5-HU Hexal, protein synthesis, fluorouracilum, G430022H21Rik, Haemato-FU, Post-Translational Protein Processing, cancer of the large bowel, Posttranslational Modifications, Fluorouracil GRY, cancer of large intestine, fluorouracilo, Posttranslational Modificationprotein translation, Post Translational Amino Acid Modification, Colorectal Neoplasm, 5 FU Medac, Post-Translational Protein Modifications, Colorectal Cancer, Carac, Neoplasms, Fluorouracil Monosodium Salt, Tumor, Haemato FU, Protein Processing, autosomal dominant, 5 Fluorouracil Biosyn, Fluorouracil-GRY, Flurodex, Posttranslational, Colorectal, colorectal cancer, Fluorouracil Mononitrate, Post Translational Modification, 2, Post-Translational Modifications, Fluoro Uracile ICN, Post Translational, Fluorouracil Potassium Salt, Colorectal Tumors, Modification, Post-Translational Protein, 5-Fluorouracil-Biosyn, Post-Translational, Efudex, Colorectal Carcinomas, 5 HU Hexal, Colorectal Tumor, Posttranslational Protein Processing, Fluracedyl, Fluorouracile Dakota, large intestine cancer, Protein Modifications, Fluorouracile, cancer of the large intestine, Post-Translational Amino Acid Modification, Posttranslational Amino Acid Modification, 3H)-Pyrimidinedione, Posttranslational Protein, 5-fluoro-, colorectal (colon or rectal) cancer., 5-Fluoropyrimidine-2, Dakota, somatic mutation, 5-FU, 5 FU Lederle, Tumors, Cancer, Post-Translational Modification, Carcinoma, protein anabolism, Fluorouracil Monopotassium Salt, 5-Fluorouracil, protein biosynthetic process, fluorouracil, Ribofluor, Modifications, 5-Fluoracil, 5-FU Medac, Post-Translational Protein Modification, Onkofluor, 5 Fluorouracil, RGD1304822, Post Translational Modifications, 4-dione, Efudix, protein formation, Neoplasm, Neofluor, protein biosynthesis, 4(1H, CRC, Colorectal Cancers, Protein Modification, Fluoro-Uracile ICN, Carcinomas, large bowel cancer, 5FU, 5-FU Lederle, Fluorouracilo Ferrer Far, Post Translational Protein Processing, mKIAA1627, Processing, susceptibility to, Colorectal Carcinoma, Adrucil, Cancers, Fluoruracil, cancer of large bowel, Fluorouracil, Post Translational Protein Modification, Fluoroplex, colon cancer, Amino Acid Modification, 5-HU Hexal, protein synthesis, fluorouracilum, G430022H21Rik, Haemato-FU, Post-Translational Protein Processing, cancer of the large bowel, Posttranslational Modifications, Fluorouracil GRY, cancer of large intestine, fluorouracilo, Posttranslational ModificationfalseThe post-translational modifications and translation-regulatory role of METTL14 in 5-fluorouracil-resistant colorectal cancerThe post-translational modifications and translation-regulatory role of METTL14 in 5-fluorouracil-resistant colorectal cancer2025-09-242023-12-02PRJNA907307GSE219173